Skip to main content
NewslettersWatchlist

Exelixis Inc(EXEL-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low34.97
Day High35.84
Open:35.30
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
3 Magnificent Stocks Under $100 to Buy in November
Motley Fool
Exelixis (EXEL) Q3 2024 Earnings Call Transcript
Motley Fool
1 No-Brainer Stock to Buy With $40
Motley Fool
2 Growth Stocks to Buy With Less Than $100
BayStreet.ca
Investors Watch Key Players in Oncology as Cancer Cases Set to Skyrocket
Motley Fool
Exelixis (EXEL) Q2 2024 Earnings Call Transcript
BayStreet.ca
Cancer Rates Surge: Key Biotech Stocks Leading the Charge in Oncology Drug Development
Motley Fool
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
Motley Fool
Exelixis (EXEL) Q1 2024 Earnings Call Transcript
Motley Fool
4 Magnificent Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Motley Fool
2 Biotech Stocks to Buy Hand Over Fist in March
Motley Fool
4 Thrilling Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Motley Fool
2 Stocks Under $30 to Buy and Hold
GlobeNewswire
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
Motley Fool
4 Appealing Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Motley Fool
Exelixis (EXEL) Q4 2023 Earnings Call Transcript
The Globe and Mail
15 overlooked U.S. mid-caps excelling in free cash flow generation
Motley Fool
Exelixis (EXEL) Q3 2023 Earnings Call Transcript
Motley Fool
4 Dominant Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Motley Fool
3 Under-the-Radar Biotech Stocks to Buy in 2023
Motley Fool
Is Exelixis Stock a Buy Now?
Motley Fool
4 Magnificent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip

Profile

Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the company's flagship molecule, which is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.